

Cristina Gasparetto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905563/publications.pdf>

Version: 2024-02-01

121
papers

1,927
citations

257450

24
h-index

289244

40
g-index

121
all docs

121
docs citations

121
times ranked

2534
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1630-1642.	10.7	237
2	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. <i>Blood</i> , 2015, 126, 2284-2290.	1.4	201
3	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2018, 132, 2546-2554.	1.4	110
4	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
5	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 999-1006.	5.8	63
6	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
7	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1872-1879.	1.3	50
8	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	1.4	49
9	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 645-645.	1.4	46
10	Panobinostat for the management of multiple myeloma. <i>Future Oncology</i> , 2017, 13, 477-488.	2.4	42
11	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	7.2	37
12	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 29.	17.0	36
13	Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 1869-1869.	1.4	36
14	Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 1888-1888.	1.4	35
15	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
16	Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8006-8006.	1.6	33
17	Recognition of early mortality in multiple myeloma by a prediction matrix. <i>American Journal of Hematology</i> , 2017, 92, 915-923.	4.1	31
18	Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 690-690.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2016, 34, 8005-8005.	1.6	29
20	Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 368-376.	0.4	28
21	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 480-485.e3.	0.4	27
22	A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 509-509.	1.4	27
23	Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 8-9.	1.4	26
24	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. Blood, 2019, 134, 142-142.	1.4	25
25	MOBILIZATION OF DENDRITIC CELLS FROM PATIENTS WITH BREAST CANCER INTO PERIPHERAL BLOOD STEM CELL LEUKAPHERESIS SAMPLES USING Flt-3-LIGAND AND G-CSF OR GM-CSF. Cytokine, 2002, 18, 8-19.	3.2	24
26	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2018, 59, 2588-2594.	1.3	22
27	Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leukemia and Lymphoma, 2016, 57, 2228-2231.	1.3	21
28	Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. British Journal of Cancer, 2022, 126, 718-725.	6.4	21
29	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. Journal of Hematology and Oncology, 2016, 9, 71.	17.0	20
30	The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. Cancer Medicine, 2018, 7, 3257-3268.	2.8	20
31	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688.	2.0	18
32	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. Transplantation and Cellular Therapy, 2021, 27, 181.e1-181.e9.	1.2	18
33	Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2019, 134, 141-141.	1.4	18
34	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 926-926.	1.4	17
35	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. Blood, 2008, 112, 93-93.	1.4	16
36	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 257-263.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. <i>Cancer Letters</i> , 2019, 440-441, 1-10.	7.2	15
38	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	2.4	15
39	Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2021, 2, 56-65.	1.0	15
40	A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 4741-4741.	1.4	15
41	Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 424-432.	0.4	14
42	Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8018-8018.	1.6	13
43	Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2). <i>Blood</i> , 2011, 118, 814-814.	1.4	13
44	Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8530-8530.	1.6	13
45	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	12
46	A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 775-784.	0.4	12
47	A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 74-74.	1.4	12
48	Stem Cell Transplantation for Multiple Myeloma. <i>Cancer Control</i> , 2004, 11, 119-129.	1.8	11
49	Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 18-19.	1.4	11
50	Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.. <i>Blood</i> , 2009, 114, 746-746.	1.4	10
51	Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 3165-3165.	1.4	9
52	Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 14-15.	1.4	9
53	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4127-4127.	1.4	9
54	â€œShort Courseâ€•Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 70-77.	2.0	7

#	ARTICLE	IF	CITATIONS
55	Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2016, 34, 8032-8032.	1.6	7
56	Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Oncology and Therapy, 2016, 4, 287-301.	2.6	6
57	Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2021, 39, 8038-8038.	1.6	6
58	Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.. Blood, 2009, 114, 306-306.	1.4	6
59	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. Blood, 2015, 126, 377-377.	1.4	6
60	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	1.7	5
61	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 2021, 11, 149.	6.2	5
62	A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 3157-3157.	1.4	5
63	Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2010, 116, 1955-1955.	1.4	5
64	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	1.4	5
65	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect MM Registry. British Journal of Haematology, 2021, 193, 93-100.	2.5	4
66	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. Transplantation and Cellular Therapy, 2021, 27, 669.e1-669.e8.	1.2	4
67	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 784.e1-784.e7.	1.2	4
68	Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Blood, 2019, 134, 3145-3145.	1.4	4
69	Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma. Blood, 2020, 136, 12-14.	1.4	4
70	Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 45-46.	1.4	4
71	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. Blood, 2013, 122, 1970-1970.	1.4	4
72	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.. Journal of Clinical Oncology, 2017, 35, 8023-8023.	1.6	3

#	ARTICLE	IF	CITATIONS
73	The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).. Journal of Clinical Oncology, 2021, 39, 7003-7003.	1.6	2
74	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. Blood Cancer Journal, 2021, 11, 92.	6.2	2
75	A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 4739-4739.	1.4	2
76	Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.. Journal of Clinical Oncology, 2018, 36, 8041-8041.	1.6	2
77	Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.. Journal of Clinical Oncology, 2019, 37, 8032-8032.	1.6	2
78	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, , .	2.4	2
79	Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect Â® Multiple Myeloma (MM) Disease Registry. Blood, 2021, 138, 117-117.	1.4	2
80	Anaplastic Multiple Myeloma: Case Series and Literature Review. , 2022, 5, 1-11.		2
81	Campath-1H May Have Activity in the Treatment of Multiple Myeloma.. Blood, 2004, 104, 4931-4931.	1.4	1
82	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.. Blood, 2005, 106, 5181-5181.	1.4	1
83	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	1.4	1
84	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 342-342.	1.4	1
85	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. Blood, 2011, 118, 2012-2012.	1.4	1
86	Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,. Blood, 2011, 118, 3985-3985.	1.4	1
87	Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients. Blood, 2011, 118, 5070-5070.	1.4	1
88	A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.. Blood, 2015, 126, 1857-1857.	1.4	1
89	PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8012-8012.	1.6	1
90	Connect MM: The multiple myeloma (MM) disease registryâ€™s incidence of second primary malignancies (SPM).. Journal of Clinical Oncology, 2012, 30, 8037-8037.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Race- and health-related quality of life among patients newly diagnosed with multiple myeloma.. Journal of Clinical Oncology, 2012, 30, e18556-e18556.	1.6	1
92	Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry.. Journal of Clinical Oncology, 2013, 31, 8586-8586.	1.6	1
93	Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 8008-8008.	1.6	1
94	Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.. Journal of Clinical Oncology, 2017, 35, 8040-8040.	1.6	1
95	Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.. Journal of Clinical Oncology, 2018, 36, 8037-8037.	1.6	1
96	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	1.4	1
97	Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM U.S. registry.. Journal of Clinical Oncology, 2013, 31, 8596-8596.	1.6	1
98	Exploring variations in multiple myeloma management through in-practice research.. Journal of Clinical Oncology, 2014, 32, e19534-e19534.	1.6	1
99	Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry.. Journal of Clinical Oncology, 2020, 38, 8518-8518.	1.6	1
100	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. Blood, 2021, 138, 1827-1827.	1.4	1
101	Reply to A. Gratwohl. Journal of Clinical Oncology, 2011, 29, e484-e484.	1.6	0
102	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biology of Blood and Marrow Transplantation, 2020, 26, 2323-2328.	2.0	0
103	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.. Blood, 2005, 106, 5501-5501.	1.4	0
104	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.. Blood, 2005, 106, 4623-4623.	1.4	0
105	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	1.4	0
106	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	1.4	0
107	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. Blood, 2008, 112, 2180-2180.	1.4	0
108	Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma.. Blood, 2009, 114, 1833-1833.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. <i>Blood</i> , 2010, 116, 3523-3523.	1.4	0
110	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. <i>Blood</i> , 2010, 116, 3541-3541.	1.4	0
111	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. <i>Blood</i> , 2011, 118, 4065-4065.	1.4	0
112	Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2909-2909.	1.4	0
113	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 5129-5129.	1.4	0
114	Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1626-1626.	1.4	0
115	Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX); Tj ETQq1 1 0.784314 rgBT /Overdo		
116	Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post-Transplant Responses Do Not Translate to Longer Survival. <i>Blood</i> , 2015, 126, 1979-1979.	1.4	0
117	Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19527-e19527.	1.6	0
118	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. <i>Blood</i> , 2019, 134, 5731-5731.	1.4	0
119	Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone. <i>Blood</i> , 2019, 134, 3177-3177.	1.4	0
120	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
121	Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 24-25.	1.4	0